Opinion|Videos|July 29, 2024
BTKi Intolerance in Real-world Practice & Management Strategy
Key opinion leaders compare and contrast the most frequently observed causes of BTK inhibitor intolerance in clinical practice among patients treated with ibrutinib, acalabrutinib, or zanubrutinib.
Advertisement
Episodes in this series
- What is the most common cause of BTKi intolerance you observe in the practice setting among patients receiving ibrutinib? Acalabrutinib or Zanubrutinib?
- At what point during treatment does intolerance typically occur?Dr davids @39:30 – dose reduce...once per day...tyr to get back up to full dose and rechallenge with acala.
- When may BTKi intolerance impact continuation of therapy and how do you manage these scenarios?
- Zanu in pts with acala/ibr intolerance –
Shadman, et al. EHA 2023. Abs P633 - Acala in pts with ibr intolerance –
Rogers, et al. Haematologica. 2021;106(9):2364-2373
- Zanu in pts with acala/ibr intolerance –
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
The OncFive: Top Oncology Articles for the Week of 8/30
5